Cost-effectiveness of the adherence with recommendations for clinical monitoring of patients with diabetes

Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3111-3121. doi: 10.1016/j.numecd.2021.07.014. Epub 2021 Jul 28.

Abstract

Background and aims: To validate a set of indicators for monitoring the quality of care of patients with diabetes in 'real-life' practice through its relationship with measurable clinical outcomes and healthcare costs.

Methods and results: A population-based cohort study was carried out by including the 20,635 patients, residents in the Lombardy Region (Italy), who in the year 2012 were newly taken-in-care for diabetes. Adherence with clinical recommendations (i.e., controls for glycated haemoglobin, lipid profile, urine albumin excretion and serum creatinine) was recorded during the first year after the patient was taken-in-care, and categorized according whether he/she complied with none or almost none (0 or 1), just some (2) or all or almost all (3 or 4) the recommendations, respectively denoted as poor, intermediate and high adherence. Short- and long-term complications of diabetes, and healthcare cost incurred by the National Health Service, were assessed during follow-up. Compared with patients with poor adherence, those with intermediate and high adherence respectively showed (i) a delay in outcome occurrence of 13 days (95% CI, -2 to 27) and 23 days (9-38), and (ii) a lower healthcare cost of 54 € and 77 €. In average, a gain of 18 Euros and 15 Euros for each day free from diabetic complication by increasing adherence respectively from poor to intermediate and from poor to high were observed.

Conclusion: Close control of patients with diabetes through regular clinical examinations must be considered the cornerstone of national guidance, national audits, and quality improvement incentive schemes.

Keywords: Complications; Cost-effectiveness; Diabetes; Healthcare cost; Incremental cost-effectiveness ratio; Periodic examinations; Population-based cohort study; Real-world.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Chemical Analysis / economics
  • Cost Savings
  • Cost-Benefit Analysis
  • Databases, Factual
  • Diabetes Mellitus / diagnosis*
  • Diabetes Mellitus / economics
  • Diabetes Mellitus / therapy*
  • Diagnostic Screening Programs / economics*
  • Diagnostic Techniques, Ophthalmological / economics
  • Female
  • Health Care Costs*
  • Humans
  • Italy
  • Kidney Function Tests / economics
  • Male
  • Middle Aged
  • National Health Programs / economics*
  • Patient Compliance*
  • Predictive Value of Tests
  • Prognosis
  • Time Factors